Sichuan Biokin Pharmaceutical (SHA:688506) said the first patient was enrolled in its phase three trial for BL-B01D1, according to a Monday filing with the Shanghai bourse.
BL-B01D1 is a dual antibody-drug conjugate (ADC) combined with Osimertinib for treating EGFR-mutated advanced non-small cell lung cancer.
Shares of the pharmaceutical company were down 4% in recent trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.